Evidence map›Paper›PMID 32328488›Full record

ArticleFrontiers in bioengineering and biotechnology2020

Characterization and Immunogenicity of HIV Envelope gp140 Zera

Phindile Ximba, Rosamund Chapman, Ann E Meyers, Emmanuel Margolin, Michiel T van Diepen, Anna-Lise Williamson, Edward P Rybicki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Vaccines · 2025
    Article
  2. Article
  3. Generation of multi-layered protein bodies inFrontiers in plant science · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Phindile XimbaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Rosamund ChapmanDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ann E MeyersBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa.
Emmanuel MargolinDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Michiel T van DiepenDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Anna-Lise WilliamsonDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Edward P RybickiBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZA

Funding

Wellcome Trust
6 · The paper itself

Abstract

HIV-1 envelope glycoprotein (Env) remains the most relevant target for the elicitation of functional antibodies to HIV by vaccination. However, soluble Env antigens often do not elicit the desired immune responses. Delivering subunit antigens on particulate nanoparticles is an established approach to improve their immunogenicity. In this study the sequence encoding Zera

Indexed as

envelope proteinHIV-1immunogenicityprotein bodyvaccineZera®

Identifiers

PMID32328488
PMCPMC7160593
OpenAlexW3016161121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.